Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5]. - It is claimed that Integer misrepresented its EP devices as a long-term growth driver, leading to misleading positive statements about its business and operations [5].

Core Insights - Intelligent Bio Solutions Inc. (INBS) has formed a strategic manufacturing partnership with Syrma Johari MedTech to enhance its production capabilities and support its entry into the U.S. market in 2026 [1][3]. Group 1: Partnership Benefits - The partnership is expected to yield annual production cost savings exceeding 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin compared to previous manufacturing arrangements [2]. - Syrma Johari's manufacturing capacity is about four times that of INBS, enabling the company to efficiently meet anticipated demand as it scales its commercial operations [2]. Group 2: Supply Chain Resilience - This collaboration strengthens INBS' global manufacturing strategy by reducing reliance on a single supplier and enhancing supply chain resilience [3]. - The partnership broadens manufacturing capacity, ensures continuity, and creates flexibility in preparation for future demand across multiple regions [3]. Group 3: Syrma Johari's Capabilities - Syrma Johari has over 45 years of experience in medical device engineering and manufacturing, operating 14 manufacturing locations and four design and innovation centers globally [4]. - The company is certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring high compliance and quality in medical device manufacturing [4]. Group 4: Production Efficiency - Syrma Johari's vertical integration and export-oriented model facilitate high-quality production while optimizing sourcing, tooling, testing, and logistics [5]. - The company is set to open a new medical-grade plastics manufacturing facility in India in January 2026, further enhancing its capabilities to meet global demand [5]. Group 5: Regulatory Support - Syrma Johari's extensive regulatory and quality-assurance capabilities align with INBS' global expansion plans, providing end-to-end quality systems and regulatory documentation support [6]. - This expertise will assist INBS in advancing its regulatory pathways and preparing for increased commercial activity worldwide [6]. Group 6: Strategic Importance - The partnership is viewed as a significant milestone for INBS, enhancing its supply chain and supporting future growth [7]. - Both companies express a strong alignment in innovation, quality, and long-term vision, indicating a commitment to scaling disruptive drug-screening technology [7][8].

Core Viewpoint - A class action has been filed against Integer Holdings Corporation (ITGR) for allegedly misleading investors about the demand for its electrophysiology (EP) devices, which has reportedly declined significantly [1][2]. Group 1: Allegations and Market Position - The complaint claims that Integer Holdings misrepresented its market position in the growing EP market and overstated the demand for its EP devices, which has actually decreased [2]. - Contrary to expectations, revenue growth from Integer's EP devices is decelerating rather than outpacing market growth [2]. Group 2: Financial Guidance and Stock Impact - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [3]. - The company acknowledged that two of its EP devices had slower than anticipated market adoption, with expectations of continued slow demand into 2026 [3]. - Following this announcement, Integer's stock price dropped by $35.22, or over 32%, closing at $73.89 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Integer Holdings, with a deadline of February 9, 2026, for those wishing to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, inclusive [1]. - Investors who purchased Integer common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a deterioration in sales for two of its electrophysiology devices [5]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about a class action lawsuit and the upcoming lead plaintiff deadline on February 9, 2026 [1] Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors wishing to serve as lead plaintiff must file a motion with the court by February 9, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5] - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5] - The lawsuit asserts that these misrepresentations led to investor damages when the true details became known [5]

Core Viewpoint - Integer Holdings Corporation (NYSE: ITGR) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [3]. - As a result, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for February 9, 2026 [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [5].

Core Insights - INVL Baltic Sea Growth Fund has sold its entire stake in MBL Group to MidEuropa, marking the fund's second exit and enabling full repayment to investors [1][2] - MBL is a leading European contract development and manufacturing organization (CDMO) specializing in assisted mobility, rehabilitation, and aged-care equipment, with significant growth in EBITDA since INVL's investment [2][3] - The transaction is seen as a strong endorsement of MBL's business model and long-term potential, with the Lauritsen family reinvesting and Martin Lauritsen continuing as CEO [1][3] Company Overview - MBL, founded in 1988 by the Lauritsen family in Denmark, is the largest European CDMO for medical mobility devices, employing approximately 1,700 professionals across Europe and Asia [2][3] - The company has over 100 registered patents and is recognized for its innovation capabilities, with projected revenue exceeding EUR 120 million by 2025 [2][3] Investment Context - The assisted mobility market is expected to grow due to factors such as population aging and increasing prevalence of chronic conditions, which aligns with MBL's strategic focus [3] - MidEuropa, a leading European private equity investor, aims to support MBL's growth and international expansion, emphasizing the investment's strong fundamentals and long-term growth potential [3][6] Fund Background - INVL Baltic Sea Growth Fund, with a size of EUR 165 million, is one of the leading private equity funds in the Baltics, backed by the European Investment Fund [4] - The fund is managed by INVL Asset Management, which has over 30 years of experience and manages more than EUR 2 billion in various investment strategies [4][5] Transaction Details - The transaction was advised by Jefferies International, with legal, financial, and commercial support from Horten, Deloitte, and L.E.K. respectively [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Integer Holdings Corporation regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and sales performance in the electrophysiology manufacturing market [1][2]. Allegations - The complaint claims that Integer Holdings Corporation overstated its competitive position within the electrophysiology manufacturing market [1]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [1]. - The company mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [1]. - As a result of these issues, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [1]. - Shareholders are encouraged to register for the class action by February 9, 2026, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses due to misleading statements or omissions [3].

Core Viewpoint - BioStem Technologies' products, VENDAJE® and VENDAJE AC®, have been granted a 12-month status quo period for reimbursement eligibility under the CMS CY 2026 Final Medicare Reimbursement Rule, ensuring continued access for patients with diabetic foot ulcers (DFU) and venous leg ulcers (VLU) [3][4]. Group 1: Reimbursement Status - The 12-month status quo designation allows BioStem's products to remain eligible for reimbursement in 2026, provided their use meets the "reasonable and necessary" standard [4]. - The Medicare Administrative Contractors (MACs) will review additional evidence by December 31, 2026, with updated determinations expected in early 2027 [4]. Group 2: Impact on Other Products - The final policy from CMS specifically applies to DFU and VLU indications, leaving reimbursement for other wound types, such as pressure ulcers, unaffected [5]. - Pressure ulcers represent the largest segment of the chronic wound market at 41%, which is crucial for BioStem's sales volume and Medicare-related revenue [5]. Group 3: Company Statements and Future Plans - The CEO of BioStem expressed appreciation for CMS's evidence-driven approach and anticipates uninterrupted payment for their products in DFU and VLU applications throughout 2026 [6]. - BioStem plans to engage with CMS and MACs to discuss clinical trial findings and aims to achieve reclassification of their products from Status Quo to Covered status during the 2027 reconsideration cycle [6].

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [3]. - As a result, the defendants' positive statements about the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for February 9, 2026 [4]. - There is no cost or obligation for shareholders to participate in the case [4].